AB1
Sickle Cell Disease
Pre-clinicalActive
Key Facts
About AkiraBio
AkiraBio is a private, preclinical-stage biotech targeting hemoglobinopathies with its lead candidate, AB1. AB1 is an oral, once-daily small molecule designed to induce fetal hemoglobin (HbF) production by inhibiting DNMT1, aiming to act as a 'functional cure' for sickle cell disease and thalassemia. The company is positioned in a high-need market with significant unmet medical need, seeking to develop a convenient, broadly accessible therapy. As a young company, it is pre-revenue and focused on advancing its lead program through clinical development.
View full company profileTherapeutic Areas
Other Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxbryta® (voxelotor) | Cleo Life Sciences | Approved |
| CT-101 | Cetya Therapeutics | Pre-clinical |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Endari (L-glutamine) | Emmaus Life Sciences | Approved |
| Digital Model for Sickle Cell Disease | Koneksa Health | Development/Validation |
| ILX-002 | Illexcor Therapeutics | Pre-clinical |
| Epeleuton | Afimmune | Phase 2 |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical or Phase 1 |
| CLY-124 | Cellarity | Phase 1 |
| Oral Decitabine/Tetrahydrouridine | Novo Nordisk | Phase 2 |
| Exagamglogene Autotemcel (CASGEVY) | Vertex Pharmaceuticals | Approved |